9:00 am Chair’s Opening Remarks

9:10 am Late Breaking Abstract: T-cell Therapy for Solid Tumors: Translational Combination Therapies

  • Prasad Adusumilli Deputy Chief and Attending, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center

9:30 am Late Breaking Abstract: Co-expression of IL-7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors Without Requiring Preconditioned Lymphodepletion

  • Zonghai Li Chief Executive Officer, CARsgen Therapeutics

9:50 am Building a digital backbone to support cell and gene therapies

Synopsis

  1. What is a digital ecosystem and when is it important to invest in and develop one?
  2. Why is a digital ecosystem valuable to CAR-T and cell & gene therapies?
  3. How can you design and build a digital ecosystem for CAR-T?

10:20 am Live Q&A with Your Expert Speakers

  • Prasad Adusumilli Deputy Chief and Attending, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center
  • Zonghai Li Chief Executive Officer, CARsgen Therapeutics
  • Rajesh Singh Managing Director, Deloitte Consulting LLP

10:35 am Virtual Speed Networking

TRANSLATION

Achieving Clinically Optimal Cell Fitness

11:30 am Mechanisms of Primary Resistance & Tumor Relapse Upon CAR T Cell Therapy in B Cell Lymphoma

  • Adrian Bot VP, Translational Medicine, Kite, a Gilead Company

11:50 am Enhancing T Cell Fitness & Expansion

12:10 pm Optimizing T-Cell Manufacturing with Next Generation Ancillary Materials

12:30 pm Live Q&A with Your Expert Speakers

Tech Slam

12:45 pm De-Risk the Fill and Finish Process Through Automation

12:55 pm Our Commitment To Providing Excellence To CAR T Cell Therapeutics

  • Teng Peng Technical Application Manager, ACROBiosystems

1:05 pm Innovate and Accelerate Cell Therapy Product Development Partnering with GenScript ProBio

  • Kenneth Lee Head of Commercial Division, Americas, GenScript ProBio

1:15 pm Refreshment Break

Synopsis

Take this break to follow up with our expert partners and explore the demo area!

Translational Experience with Allogeneic CAR & TCR Therapy

1:45 pm Non-Gene Edited Approaches for Allogeneic CAR-T Cell Therapies

2:10 pm Gene-Edited Allogeneic CAR-T Cell Therapies

2:35 pm Genetically Engineered Allogeneic NK Cell lines for Treatment of Cancer & Viral Infections

3:00 pm Refreshment Break

3:10 pm Diversity in CAR-TCR Panel Discussion

  • Shon Green Head of Translational R&D, Umoja Biopharma
  • Adrienne Farid CDO, Century Therapeutics
  • Delfi Krishna Director, Operations, Planning, Strategy, Cell & Gene Therapy, GlaxoSmithKline
  • Krishnan Viswanadhan Senior Vice President, Global Cell Therapy Franchise Lead, Bristol-Myers Squibb
  • Agnes Yeboah Executive Director, Global Regulatory CMC - Biologics & Cell Therapy, Bristol Myers Squibb

4:10 pm Refreshment Break

Benchmark Clinical Biomarkers to Determine Safety & Efficacy

4:20 pm Development of an Allogeneic, Off-the-Shelf T-cell Immunotherapy & Derivation of a Next-Generation CAR-T Platform

  • Blake Aftab VP Preclinical & Translational Science, Atara Biotherapeutics

4:45 pm Using Red Cell TherapeuticsTM to Enhance Antitumor Immune Responses

Strategies to Manage & Prevent Toxicity

5:10 pm CRS Management & Prevention

  • Deepu Madduri Assistant Director, Cellular Therapy, The Mount Sinai Hospital

5:35 pm Chair’s Closing Remarks

5:40 pm Post-Conference Networking

Synopsis

Follow up with those you have met online during the conference or join the open networking room to discuss the day with your colleagues.